Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19246232 | 0.92 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10304159 | 0.89 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL11328512 | 0.88 | — | — | |
| SCHEMBL17601882 | 0.87 | — | — | |
| SCHEMBL6560470 | 0.87 | GBA1 (0.39) | — | |
| SCHEMBL11324571 | 0.85 | GBA1 (0.42) | — | |
| SCHEMBL17616826 | 0.83 | — | — | |
| SCHEMBL5029018 | 0.83 | — | — | |
| SCHEMBL500116 | 0.80 | — | — | |
| SCHEMBL12935471 | 0.80 | EED (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8106021-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP3 | CYP1A2 2677/4885CYP2D6 1854/4885CYP2C19 2026/4885 |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | CYP1A2 585/4885CYP2D6 341/4885CYP2C19 345/4885 |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | FKBP5, FKBP1A, FKBP3 | CYP1A2 2677/4885CYP2D6 1854/4885CYP2C19 2026/4885 |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | CYP1A2 585/4885CYP2D6 341/4885CYP2C19 345/4885 |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | CYP1A2 585/4885CYP2D6 341/4885CYP2C19 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.